Device-related adverse events

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period

The most common adverse event was vaginal wall injury, with most adverse events (90/134, 67%) occurring during the fitting period rather than the treatment period. No serious device-related adverse ev

Effect: adverse; 28/73 (38%) experienced mild or moderate device-related AEs during treatment period